Total number of projects: 2
As coordinator: 0
As participant: 2
Sole participant: 0
Coordinator / Participant Ratio: 0*
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2013 | 0 | 5.999.995 | 443.764 | 1 | ||
2011 | 0 | 5.997.996 | 100.752 | 1 |
Total number of partners: 57
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 57
Frequent / Rare Partner Ratio: 0
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2013-12-01 | A Phase Ib/II study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor PF-02341066 in KRASMT and KRASWT (with aberrant c-MET) Colorectal Cancer Patients | MERCURIC | participant | 5.999.995 | 13 |
2011-11-01 | Epilepsy Pharmacogenomics: delivering biomarkers for clinical use | EpiPGX | participant | 5.997.996 | 15 |